Clinical trial
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
NCT00331994 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00331994 |
|---|---|
| Title | EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth |
| Official title | Efficacy Evaluation of Enterogermina, 2 Billion Bacillus Clausii Spores, on Eradication of Small Intestinal Bacterial Overgrowth: a Randomised, Parallel-group, Open Study. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome |
| Intervention type | Drug |
| Interventions | Bacillus clausii, Metronidazole |
| Enrollment | 250 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | May 31, 2006 |
| Last update posted | Jul 20, 2009 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: